Sandimmun Optoral
Phase 3Small molecule
NovartisSandimmun Optoral is one of 32 small molecule programs targeting Heart Transplant Rejection. It is currently in Phase 3.
2
Indications
1
Total Trials
0
Active Trials
31
Competitors
Pipeline
Status by Indication[3][1]
Competition
Competitive Landscape
476 competitors in Kidney Transplant
#DrugCompanyPhaseTrials
1Simulect
NovartisPreclinical
Medrol
PfizerPreclinical
Sandimmun Optoral
NovartisPhase 3
Sensipar
AmgenPreclinical
Epogen
Johnson & Johnson Pharmaceutical Research & Development, L.L.C.Preclinical
Cysteine Hydrochloride
NovartisPreclinical
Radicava
ShionogiPreclinical
Precedex
MMcNeil Consumer & Specialty Pharmaceuticals, a Division of McNeil-PPC, Inc.
Preclinical
Jardiance
Boehringer IngelheimPreclinical
Nydrazid
KKaruna Therapeutics, Inc., a Bristol Myers Squibb company
Preclinical
Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.
Clinical
Trials by Indication[1]
Sources
References
- [1]
- [2]
- [3]Open Targets Platform — Drug–disease associations for Sandimmun Optoral. EMBL-EBI & Wellcome Sanger Institute.
- [4]